AVIVA STRATEGIES (FKA MGB CONSULTING)

Lobbying for ENDEAVOR BIOMEDICINES · Biotechnology & therapeutics

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · California · House · Senate · $51,000.00 income · posted Apr 15, 2026

Lobbying activity 1

Health Issues

FAIR Act FDA Modernization

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem